Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of TScan Therapeutics's TSC-101?
TSC-101 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Myelodysplastic Syndrome. According...
TSC-101 by TScan Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
TSC-101 by TScan Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
TSC-101 by TScan Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...